Cetuximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Cetuximab
- Pharmacist Assessment Report
- Cetuximab: From Colorectal Cancer and Head and Neck Squamous Cell Carcinoma to Ductal or Ductular Proliferation
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cetuximab: From Colorectal Cancer and Head and Neck Squamous Cell Carcinoma to Ductal or Ductular Proliferation
One-Sentence Summary
Cetuximab is an anti-EGFR antibody used for EGFR-expressing metastatic colorectal cancer and squamous cell cancers of the head and neck. The TxGNN model predicts it may be effective for ductal or ductular proliferation, a non-specific histological term. No clinical trials and 20 publications were retrieved, but none studies this condition directly: they concern pancreatic ductal adenocarcinoma (PDAC) and related topics.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Colorectal cancer and squamous cell carcinoma, including head and neck (relations recorded in the knowledge graph; the licence records contain no indication text) |
| Predicted New Indication | Ductal or ductular proliferation |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is used for EGFR-expressing metastatic colorectal cancer after other chemotherapy has failed. It is also used for squamous cell head and neck cancers, in combination with radiotherapy. Detailed mechanism-of-action data were not available in the compiled data, so this description comes from its pharmacology record.
The predicted term “ductal or ductular proliferation” is a general histological label. It is not equivalent to pancreatic ductal adenocarcinoma (PDAC). The retrieved literature mostly concerns PDAC, where EGFR is commonly overexpressed and signals through KRAS. That is a loose biological link at best.
Several points weaken the case:
- KRAS mutation, found in most PDAC, is a known negative predictor of benefit from anti-EGFR antibodies.
- Preclinical work describes cetuximab resistance in PDAC cells, for example through integrin β1–Src–Akt bypass signalling.
- Several papers address KRAS inhibitors, other ERBB inhibitors, or imaging and photoimmunotherapy rather than cetuximab treatment itself.
The prediction is therefore a model-generated hypothesis with no direct supporting study.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of these publications studies “ductal or ductular proliferation” itself. They address pancreatic ductal adenocarcinoma or related topics.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35300246 | 2022 | Randomized phase II trial | Clin Transl Radiat Oncol | Long-term results of cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer (PARC trial) |
| 21552097 | 2012 | Phase II study | Am J Clin Oncol | Gemcitabine, oxaliplatin and cetuximab in locally advanced or metastatic pancreatic cancer |
| 22571859 | 2012 | Clinical study | Ann Oncol | Neoadjuvant cetuximab, twice-weekly gemcitabine and IMRT in localized or locally advanced pancreatic adenocarcinoma |
| 26862857 | 2016 | Exploratory trial analysis | Oncotarget | miR-21 expression and outcome in locally advanced pancreatic cancer in the PERU trial (chemoradiotherapy with or without cetuximab) |
| 23992319 | 2014 | Review | Curr Med Chem | Targeted therapies in pancreatic carcinoma, including monoclonal antibodies |
| 32699558 | 2020 | Review | Ther Adv Med Oncol | Precision medicine in metastatic PDAC |
| 27797376 | 2017 | Preclinical | Oncogene | Cetuximab resistance in PDAC cells via integrin β1–Src–Akt bypass signalling; co-targeting EGFR and neuropilin-1 overcomes it |
| 30921351 | 2019 | Preclinical | PLoS One | Mesothelin and TGF-α predict PDAC cell sensitivity to EGFR inhibitors, including cetuximab |
| 37844759 | 2024 | Modelling study | J Pharm Sci | PK/PD modelling of cetuximab distribution in pancreatic tumor models with smoothened inhibitor priming |
| 36383067 | 2022 | Review | Mol Oncol | Noncovalent KRASG12D inhibitor in pancreatic and colorectal cancer (not cetuximab-specific) |
India Market Information
All three records are single-ingredient products from Merck Ltd, currently valid. The licence records contain no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 73420 | Erbitux 500mg Infusion | Bottle of 50 ml infusion | Not stated in the licence record |
| 73829 | Erbitux 100mg Infusion | Bottle of 50 ml infusion | Not stated in the licence record |
| 74511 | Erbitux 5mg/ml Solution for Infusion | Bottle of 20 ml solution for infusion | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 20 interaction records were found.
- Major: aminolevulinic acid and thalidomide.
- Moderate:
- Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole).
- Chemotherapy agents (capecitabine, fluorouracil, carboplatin, cisplatin, oxaliplatin).
- Others (idelalisib, omacetaxine mepesuccinate, methoxsalen, verteporfin, topical aminolevulinic acid, topical methyl aminolevulinate).
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has a very high model score but no direct clinical or preclinical study of the predicted condition.
- The term is non-specific, and the nearest related disease (PDAC) carries KRAS-mediated resistance to anti-EGFR antibodies.
To proceed, the following is needed:
- A precise definition of the target condition: benign ductal or ductular proliferation versus a malignant entity such as PDAC.
- Studies that directly address that condition, such as biomarker work (KRAS status, EGFR expression) or early-phase trials.
- The package insert content for warnings, contraindications and approved indications of the Indian Erbitux products.
- Detailed mechanism-of-action data and a safety assessment for any non-oncology or pre-malignant use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.